Thu Sep 12 00:05:43 UTC 2024: ## New Genomic Test Shows Promise for Treating Aggressive Breast Cancer

**Barcelona, Spain** – A new genomic test, TNBCDX®, has been developed and validated for patients with early-stage Triple-Negative Breast Cancer (TNBC). This significant advancement, presented at the ESMO Congress 2024 in Barcelona, offers hope for tailoring treatment plans and improving outcomes for this particularly challenging form of breast cancer.

TNBC is known for its aggressive nature and lack of effective treatment options due to the absence of hormone receptors and HER2 expression. While current therapies often involve harsh and expensive regimens, TNBCDX® helps identify patients who might benefit from less intensive treatments.

Two independent studies involving 418 patients showed a strong correlation between TNBCDX® scores and key indicators like pathological complete response (pCR), distant disease-free survival (DDFS), and overall survival (OS). The test even outperformed existing methods like tumor-infiltrating lymphocytes (TILs) in predicting these outcomes.

Dr. Miguel Martin, a leading breast cancer expert, highlighted the importance of TNBCDX® in guiding treatment decisions and refining risk stratification. “This test will enable oncologists to tailor treatments more effectively, offering new hope for individuals managing this aggressive form of breast cancer,” he stated.

TNBCDX® integrates clinical variables with key tumor and immune biological factors across 15 genes, providing a comprehensive risk assessment. It includes two scores: a risk score and a pCR likelihood score. The test also measures ERBB2 levels to confirm the accurate classification of TNBC.

While currently available in a Research Use Only (RUO) format, REVEAL GENOMICS, the company behind TNBCDX®, is working to standardize the assay and make it accessible through the Biomedical Diagnostic Center (CDB) at Hospital Clínic by 2025.

This groundbreaking development marks a significant step towards personalized medicine for TNBC patients. With its ability to provide crucial genomic insights, TNBCDX® holds the potential to transform the treatment landscape for this aggressive form of breast cancer and offer new hope for patients.

Read More